Sabizabulin + Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator
Phase 2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer
Trial Timeline
Mar 15, 2023 → May 26, 2024
NCT ID
NCT05079360About Sabizabulin + Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator
Sabizabulin + Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator is a phase 2 stage product being developed by Veru for Metastatic Breast Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05079360. Target conditions include Metastatic Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Breast Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05079360 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Metastatic Breast Cancer